S
Seres Therapeutics, Inc. (MCRB)
NMS – Real Time Price. Currency in USD
7.08
+0.23 (3.43%)
At close: Jun 26, 2026, 4:00 PM EDT
7.08
0.00 (0.00%)
After-hours: Jun 26, 2026, 5:04 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
7.08
+0.23 (3.43%)
At close: Jun 26, 2026, 4:00 PM EDT
7.08
0.00 (0.00%)
After-hours: Jun 26, 2026, 5:04 PM EDT
No Data
There are no news for this stock.
Total debt $80.5M significantly exceeds cash reserves ($29.8M), raising financial stability concerns
Total current assets $31.8M exceed Total current liabilities $19.3M, highlighting excellent liquidity
Debt-to-equity ratio (3.0) far exceeds the industry average, reflecting over-leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$16.4M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.65 | 6.05 | 8.0 | |
| Quick ratio | 1.65 | 5.63 | 8.0 | |
| Debt to Equity | 3.04 | 0.30 | 2.0 | |
| Debt to Assets | 0.68 | 1.04 | 3.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 4.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 7M | N/A | N/A | 789K | 1M |
| Gross Profit | -5M | -15M | -15M | -3M | -3M |
| Operating Income | -245M | -195M | -118M | -94M | -87M |
| Net Income | -250M | -114M | -147M | 6M | -47M |
| EBITDA | -234M | -180M | -103M | -90M | -83M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 3.74 | 2.5 |
| Next quarter | 3461.25 | -273.94 | 5.5 |
| Current year | 1529.66 | -1274.22 | 5.5 |
| Next year | -97.22 | 12.51 | 4.5 |
| Weighted average score | 4.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -18.25 | -29.84 | -16.84 | -10.99 | 1.0 |
| Y/Y | 999 | -160.92 | -155.46 | -160.86 | 3.3 |
| 3y average | 632.67 | 43.19 | 386.82 | 43.06 | 10 |
| 5y average | 427.85 | -25.08 | 195.07 | -1593.12 | 5.5 |
| Weighted average score | 5.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |